Supplementary Fig. S3 from Flumatinib Versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study

Li Zhang,Li Meng,Bingcheng Liu,Yanli Zhang,Huanling Zhu,Jiuwei Cui, Aining Sun,Yu Hu,Jie Jin,Hao Jiang,Xi Zhang,Yan Li,Li Liu,Wanggang Zhang,Xiaoli Liu,Jian Gu,Jianhui Qiao,Guifang Ouyang,Xin Liu,Jianmin Luo,Ming Jiang,Xiaobao Xie,Jianyong Li, Chunting Zhao,Mei Zhang,Tonghua Yang,Jianxiang Wang

crossref（2023）

引用 0|浏览5
摘要
Time to MMR (A) and CCyR (B) MMR, and (C) Kaplan-Meier estimate of probability of progression to AP/BC or death due to CML while on treatment.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
0
您的评分 :

暂无评分

数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn